{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:23:23Z","timestamp":1783362203676,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/bjc.2015.256","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T22:46:16Z","timestamp":1437086776000},"page":"396-402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer"],"prefix":"10.1038","volume":"113","author":[{"given":"Ruud","family":"van der Noll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja W J","family":"Mergui-Roelvink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Rehorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H M","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"key":"BFbjc2015256_CR1","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785\u20133790.","journal-title":"J Clin Oncol"},{"key":"BFbjc2015256_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1470-2045(12)70153-5","volume":"13","author":"N Bennet","year":"2012","unstructured":"Bennet N (2012) No survival benefit of olaparib in ovarian cancer patients. Lancet Oncol 13: 192.","journal-title":"Lancet Oncol"},{"key":"BFbjc2015256_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913\u2013917.","journal-title":"Nature"},{"key":"BFbjc2015256_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/bies.1115","volume":"23","author":"A B\u00fcrkle","year":"2001","unstructured":"B\u00fcrkle A (2001) Physiology and pathophysiology of poly(ADP-ribosyl)ation. Bioessays 23: 795\u2013806.","journal-title":"Bioessays"},{"key":"BFbjc2015256_CR5","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1073\/pnas.94.14.7303","volume":"94","author":"JM De Murcia","year":"1997","unstructured":"De Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Javier Oliver F, Masson M, Dierich A, LeMeur M, Waltzinger C, Chambon P, de Murcia G (1997) Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 94: 7303\u20137307.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc2015256_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","volume":"10","author":"KJ Dedes","year":"2011","unstructured":"Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS (2011) Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell cycle 10: 1192\u20131199.","journal-title":"Cell cycle"},{"key":"BFbjc2015256_CR7","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","volume":"18","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WTA, Friberg LE, Schiavon G, Wiemer EAC, Verweij J, Loos WJ, Mathijssen RHJ, De Giorgi U (2012) A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 18: 5780\u20135787.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2015256_CR8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NMB, Jackson SP, Smith GCM, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917\u2013921.","journal-title":"Nature"},{"key":"BFbjc2015256_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Engl J Med 361: 123\u2013134.","journal-title":"N Engl J Med"},{"key":"BFbjc2015256_CR10","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852\u2013861.","journal-title":"Lancet Oncol"},{"key":"BFbjc2015256_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5: 387\u2013393.","journal-title":"Mol Oncol"},{"key":"BFbjc2015256_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2014","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma\u00f1a J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2014) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 33: 244\u2013250.","journal-title":"J Clin Oncol"},{"key":"BFbjc2015256_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/bjc.2011.8","volume":"104","author":"OA Khan","year":"2011","unstructured":"Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, Margison GP, Califano R, Larkin J, Wellman S, Middleton MR (2011) A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 104: 750\u2013755.","journal-title":"Br J Cancer"},{"key":"BFbjc2015256_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","volume":"39","author":"R Krishnakumar","year":"2010","unstructured":"Krishnakumar R, Kraus WL (2010) The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39: 8\u201324.","journal-title":"Mol Cell"},{"issue":"suppl","key":"BFbjc2015256_CR15","doi-asserted-by":"crossref","first-page":"abstract 5505","DOI":"10.1200\/jco.2013.31.15_suppl.5505","volume":"31","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin GJS, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Macpherson E, Dougherty B, J\u00fcrgensmeier JM, Orr M, Matulonis U (2013) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol (Meeting Abstracts) 31 (suppl): abstract 5505.","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"BFbjc2015256_CR16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"JA Ledermann","year":"2012","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin GJS, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366: 1382\u20131392.","journal-title":"N Engl J Med"},{"key":"BFbjc2015256_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"JA Ledermann","year":"2014","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustni GJS, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15: 852\u2013861.","journal-title":"Lancet Oncol"},{"key":"BFbjc2015256_CR18","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1021\/jm8001263","volume":"51","author":"KA Menear","year":"2008","unstructured":"Menear KA, Adcock C, Boulter R, Cockroft X, Copsey L, Cranston A, Dillon KL, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM, Matthews ITW, Moore S, O'Connor MJ, Smith GCM, Martin NMB (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51: 6581\u20136591.","journal-title":"J Med Chem"},{"key":"BFbjc2015256_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RHJ, Sonke GS, Colombo N, \u0160pa\u010dek J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16: 87\u201397.","journal-title":"Lancet Oncol"},{"key":"BFbjc2015256_CR20","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","volume":"18","author":"A Rajan","year":"2012","unstructured":"Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G (2012) A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumours. Clin Cancer Res 18: 2344\u20132351.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2015256_CR21","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AOH, Zander SAL, Derksen PWB, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NMB, Borst P, Jonkers J (2008) High sensitivity of BRCA1-deficient mammary tumours to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105: 17079\u201317084.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc2015256_CR22","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","volume":"30","author":"J Samol","year":"2012","unstructured":"Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, Cassidy J (2012) Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumours: a phase I study. Invest New Drugs 30: 1493\u20131500.","journal-title":"Invest New Drugs"},{"key":"BFbjc2015256_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2009.10.021","volume":"46","author":"SK Sandhu","year":"2010","unstructured":"Sandhu SK, Yap TA, de Bono JS (2010) Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46: 9\u201320.","journal-title":"Eur J Cancer"},{"key":"BFbjc2015256_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.vph.2010.06.003","volume":"53","author":"RK Sodhi","year":"2010","unstructured":"Sodhi RK, Singh N, Jaggi AS (2010) Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vascul Pharmacol 53: 77\u201387.","journal-title":"Vascul Pharmacol"},{"key":"BFbjc2015256_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92: 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2015256_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176\u2013181.","journal-title":"Semin Radiat Oncol"},{"key":"BFbjc2015256_CR27","doi-asserted-by":"crossref","first-page":"abstract 2579","DOI":"10.1200\/jco.2013.31.15_suppl.2579","volume":"31","author":"R Van der Noll","year":"2013","unstructured":"Van der Noll R, Ang JE, Jager A, Marchetti S, Mergui-Roelvink M, de Bono JS, Lolkema MP, Brunetto A, Arkenau HT, de Jonge MJA, van der Biessen D, Tchakov I, Bowen K, Schellens JHM (2013a) Phase I study of olaparib in combination with carboplatin and\/or paclitaxel in patients with advanced solid tumours. J Clin Oncol 31: abstract 2579.","journal-title":"J Clin Oncol"},{"key":"BFbjc2015256_CR28","first-page":"S174","volume":"49","author":"R Van der Noll","year":"2013","unstructured":"Van der Noll R, de Gr\u00e8ve J, Jager A, Marchetti S, Mergui-Roelvink M, de Jonge MJA, van der Biessen D, Tchakov I, Bowen K, Schellens JHM (2013b) Safety results from a Phase I study with a new tablet formulation of olaparib (O) in combination with carboplatin (C) and paclitaxel (Pa). Eur J Cancer 49: S174\u2013S175.","journal-title":"Eur J Cancer"},{"key":"BFbjc2015256_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3322\/caac.20095","volume":"61","author":"TA Yap","year":"2011","unstructured":"Yap TA, Sandhu SK, Carden CP, de Bono JS (2011) Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61: 31\u201349.","journal-title":"CA Cancer J Clin"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2015256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015256","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:29:30Z","timestamp":1684416570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2015256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["BFbjc2015256"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2015.256","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"26 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}